Jeff Aronin has nearly 20 years of experience developing global biotech and healthcare innovation companies. His expertise in complex science, rare diseases, and drug development has made him one of the most successful and innovative leaders in the bioscience sector.

Jeff has a passion for bringing talented teams of scientists and business executives together to research drug treatments and therapies. His teams have a proven track record of bringing new medicines to market with the goal of improving the lives of often overlooked patients. Jeff and his teams have succeeded in getting 13 Novel Drug Approvals through the FDA—a success rate higher than most other peers in the U.S. healthcare sector. 

In addition to putting his experience and passion to work building bioscience firms, Jeff serves as a mentor to many, sharing his expertise with budding entrepreneurs.



Problems people have deemed unsolvable are problems worth solving.”
— Jeff Aronin


Jeff is currently chairman and chief executive officer of Paragon Biosciences, LLC. Paragon Biosciences is focused on improving the lives of patients suffering from debilitating diseases by building innovative biotechnology companies that bring important medicines to the market. The company's leadership and management team leverages their entrepreneurial experiences, and their expertise in securing 13 FDA drug approvals, to develop and finance biotechnology companies and accelerate their advancements. Patients come first, as Paragon’s family of companies power medical breakthroughs with the support and collaboration of health care providers and key stakeholders involved in delivering healthcare services. Jeff is the co-founder and non-executive chairman of Castle Creek Pharma and non executive chairman of Harmony Biosciences.


Jeff has served as chairman of a number of biotech and pharma companies, including Paragon Pharmaceuticals, MedCare Technologies, and Marathon Pharmaceuticals. Previously, Jeff served as president and chief executive officer of Ovation Pharmaceuticals Inc., a biopharmaceutical company he founded in 2000. In 2009, Ovation Pharmaceuticals was acquired by Lundbeck, Inc. 


Throughout his career, Jeff has received honors for his entrepreneurship and patient-focused dedication to bringing new medicines to market. These achievements include: the 2017 Weizmann Leadership Award, Brain Research Foundation, Frederic A. Gibbs Discovery Award, 2013; Buyouts magazine "Deal of the Year" 2010, Ovation Pharmaceuticals; Illinois Holocaust Museum & Education Center's Humanitarian Award, 2010; Pharmaceutical Executive magazine's "45 under 45," 2008; Epilepsy Foundation of Greater Chicago, Rovner Award, 2007; Scrip Award "Pharma Company of the Year-Small and Medium-sized Enterprises," 2006, 2007, Ovation Pharmaceuticals; and the Ernst & Young "Entrepreneur of the Year" among Emerging Companies (Lake Michigan area), Finalist 2006, 




Jeff seeks to make a difference in the community by supporting a wide range of not-for-profit organizations. 


Disease StateS

Jeff supports numerous organizations dedicated to improving patient outcomes for a variety of disease states. These entities include Susan G. Komen, Juvenile Diabetes Research Foundation, Cystic Fibrosis Foundation, JED Foundation for Depression, Pharmacological Treatment of Epilepsy, Liver Life Challenge, and Pediatric Sun Protection Foundation

All Paragon companies are committed to making a difference:

  • In the communities they treat
  • Disease states they are focused on
  • Employees share the same philanthropic vision as leadership 



To contact Jeff, please fill out the form at right. For business and media inquiries please use the contact information available at Paragon Biosciences, LLC by visiting the company's website


Please complete the form below

Name *